ReviewAsian Pacific journal of cancer prevention : APJCP2026
Cancer Vaccines: Mobilizing Immunity for Targeted Cancer Therapy.
Review in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCancer remains the leading cause of mortality in economically developed nations, presenting a major global health burden. Conventional anti-cancer therapies, such as chemotherapy and radiotherapy, often fall short of providing safe, targeted, and long-lasting treatments, particularly for aggressive and metastatic cancer types.
methodIn recent years, cancer immunotherapy has emerged as a promising alternative that harnesses the patient's own immune system to recognize and eliminate malignant cells. Among the various immunotherapeutic strategies, cancer vaccines represent a dynamic and rapidly evolving field. These vaccines aim to stimulate or enhance tumor-specific immune responses and are tailored to target the diverse molecular and immunological hallmarks of cancer.
resultWhile several cancer vaccines have gained regulatory approval and entered clinical use, many others remain under investigation, requiring further optimization and evaluation through clinical trials.
conclusionThis review provides an overview of both clinically approved and emerging cancer vaccine strategies. Additionally, it examines the underlying factors that influence their clinical efficacy and translational potential, including immune evasion, delivery challenges, and patient-specific variables.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.